We are live on ! Find out more
CC

Checkpoint Capital Portfolio holdings

AUM $279M
1-Year Est. Return 45.74%
This Fund
S&P 500
This Quarter Est. Return
+23.5%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$202M
AUM Growth
+$35.7M
Cap. Flow
+$4.7M
Cap. Flow %
2.33%
Top 10 Hldgs %
95.37%
Holding
19
New
3
Increased
6
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$15.4M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$8.8M
3
ARGX icon
argenx
ARGX
+$5.23M
4
TCRX icon
TScan Therapeutics
TCRX
+$4.98M
5
STOK icon
Stoke Therapeutics
STOK
+$2.23M

Top Sells

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.4M
2
CORT icon
Corcept Therapeutics
CORT
+$7.95M
3
AXSM icon
Axsome Therapeutics
AXSM
+$7.08M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$4.65M
5
KYMR icon
Kymera Therapeutics
KYMR
+$2.45M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.1B
$50.1M 24.88%
92,500
+10,350
+13% +$5.23M
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.96B
$34.8M 17.24%
663,381
-258,719
-28% -$12.4M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$692M
$27.2M 13.49%
1,504,307
+629,307
+72% +$8.8M
CYTK icon
4
Cytokinetics
CYTK
$10.4B
$24.6M 12.23%
466,813
+276,813
+146% +$15.4M
AXSM icon
5
Axsome Therapeutics
AXSM
$10.9B
$18.8M 9.35%
209,632
-81,140
-28% -$7.08M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$14.4M 7.16%
1,100,000
-38,178
-3% -$582K
PTGX icon
7
Protagonist Therapeutics
PTGX
$9.44B
$10.8M 5.36%
240,000
-115,000
-32% -$4.65M
PLRX icon
8
Pliant Therapeutics
PLRX
$65M
$4.26M 2.11%
380,000
+147,800
+64% +$1.85M
TCRX icon
9
TScan Therapeutics
TCRX
$52M
$4.11M 2.04%
+825,341
New +$4.98M
ATYR
10
aTyr Pharma
ATYR
$50.1M
$3.06M 1.52%
1,736,477
-210,000
-11% -$382K
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$2.93M 1.45%
57,983
+38,288
+194% +$1.83M
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$1.96M 0.97%
182,426
+37,009
+25% +$444K
STOK icon
13
Stoke Therapeutics
STOK
$2.11B
$1.94M 0.96%
+157,514
New +$2.23M
IRON icon
14
Disc Medicine
IRON
$2.97B
$1.26M 0.62%
+25,543
New +$1.2M
TRVI icon
15
Trevi Therapeutics
TRVI
$2.64B
$835K 0.41%
250,000
-250,089
-50% -$743K
ALLK
16
DELISTED
Allakos
ALLK
$425K 0.21%
649,957
– –
APLT
17
DELISTED
Applied Therapeutics
APLT
– –
-227,470
Closed -$1.06M
CORT icon
18
Corcept Therapeutics
CORT
$12B
– –
-244,750
Closed -$7.95M
KYMR icon
19
Kymera Therapeutics
KYMR
$8.94B
– –
-82,000
Closed -$2.45M

Similar funds

CB
Centennial Bank Conway, Arkansas $279M AUM 20.11% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Checkpoint Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Checkpoint Capital held 19 positions worth $202M, up 22% from $166M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Checkpoint Capital's Q3 2024 filing shows 3 new, 6 increased, 6 reduced and 3 closed positions. Its largest new stake was TScan Therapeutics: 825,341 shares worth $4.11M. The largest sale was Rhythm Pharmaceuticals, an estimated $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Checkpoint Capital's largest Q3 2024 buy was TScan Therapeutics: 825,341 shares worth $4.11M.
  • Checkpoint Capital added most to Cytokinetics in Q3 2024, an estimated $15.4M increase.
  • Checkpoint Capital's biggest Q3 2024 reduction was Rhythm Pharmaceuticals, cutting an estimated $12.4M.
  • Checkpoint Capital fully exited Corcept Therapeutics in Q3 2024, selling an estimated $7.95M.
  • Checkpoint Capital's ten largest holdings make up 95% of its $202M portfolio in Q3 2024.
  • Checkpoint Capital opened 3 new positions and closed 3 in Q3 2024.
  • Checkpoint Capital's portfolio value rose 22% quarter-over-quarter to $202M.

Based on Checkpoint Capital's 13F filing for Q3 2024, filed 14 Nov 2024.